Summit Therapeutics plc Stock: price and insider trades · United Kingdom
No insider purchase over the last 90 days. The latest, by (i) Dr Elaine Stracker, was filed 10 Feb 2020.
Summit Therapeutics plc: what insiders have been doing
Summit Therapeutics plc is a listed company. Filings by its managers are published through RNS (LSE). Summit Therapeutics plc has had no insider filing for more than a year; the last one goes back to 10 February 2020.
Since 2018, the database holds 3 purchases and 1 sale by insiders of the company.
Source: insider filings from RNS (LSE). Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
- 2,099,207 sharesOutside a trading venueISIN GB00BN40HZ01FCA-NSM:NASDAQ_1000317870-en_20200331164940286_8676Canonical exit: 7 May 2020 (T+90)
- 11,358 shares@ £0.281100.0% of flowLondon Stock ExchangeISIN GB00BN40HZ01FCA-NSM:NASDAQ_1000103537-en_20200330111442478_7053-1
- 25,000 shares@ £0.395100.0% of flowLondon Stock ExchangeISIN GB00BN40HZ01FCA-NSM:HUGIN2205537_5_20200330111420425_12900Canonical exit: 14 Oct 2018 (T+90)
- 150,000 shares@ £0.38100.0% of flowLondon Stock ExchangeISIN GB00BN40HZ01FCA-NSM:HUGIN2205330_3_20200330111420484_14132Canonical exit: 11 Oct 2018 (T+90)
- 17,500 sharesOutside a trading venueISIN GB00BN40HZ01FCA-NSM:HUGIN2186360_35_20200330111352472_6975-1
5 of 5 declarations
About Summit Therapeutics plc
Summit Therapeutics plc is a biopharmaceutical company focused on developing treatments for infectious diseases and muscle disorders. It emphasizes innovation in targeted therapies.
